News for Compugen Ltd. (CGEN)

PR NewswireHOLON, Israel, March 4, 2025 In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd

PR NewswireHOLON, Israel, March 4, 2025 Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG an

PR NewswireHOLON, ISRAEL, March 3, 2025 HOLON, ISRAEL , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer im

PR NewswireHOLON, Israel, Feb. 26, 2025 Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Un

PR NewswireHOLON, Israel, Feb. 18, 2025 HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immu

This is our list of the best penny stocks to watch, based on a review of stocks that had positive performance over the last 30 days.

Compugen Ltd (CGEN), a clinical-stage therapeutic discovery and development company, saw its stock rise by 5% to $1.66 with a trading volume of 315,350 shares.

PR NewswireHOLON, Israel, Nov. 27, 2024 Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT

Compugen Ltd. (CGEN), a clinical-stage therapeutic discovery and development company, recently experienced a significant stock fluctuation with a 5.17% drop in

Start Time: 08:30 January 1, 0000 9:30 AM ETCompugen Ltd.

The Bioinformatics Market Size sector reached a market value of USD 20.72 Billion in 2023. Future projections show a bright outlook, with a Compound Annual Growth Rate (CAGR) of 17.6% from 2023 to…

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Aug 06, 2024 / 12:30PM GMTOperator Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's second quarter 2024 Results conference call. At t

Compugen Ltd. (NASDAQ:NASDAQ:CGEN) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ETCompany ParticipantsYvonne Naughton - Head of Investor...

Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease.

bluebird bio, Inc. (BLUE) is down over 30% at $1.68. The following are some of the other stocks making big moves in Wednesday's pre-market trading..

bluebird bio, Inc. (BLUE) is down over 30% at $1.68. The following are some of the other stocks making big moves in Wednesday's pre-market trading..

ARKK and STMZF both seek to capitalize on the upcoming tech revolution. Funds are considered undervalued and have performed adequately to stupendously in the long run. Read more here.

Israeli bank and insurance company shares were more than 2.5% lower on the Tel Aviv Stock Exchange (TASE) on Sunday following the failure of SVB Financial Group late last week, while the government